LIVIVO - Search results -

Search results

Result 1 - 10 of total 12

Search options

Article ; Online: Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker.

2023 Volume 12, Issue 6

Abstract: Glioblastoma (GBM) is the most frequent primary malignant brain tumor and has a dismal prognosis. Unfortunately, despite the recent revolution of immune checkpoint inhibitors in many solid tumors, these have not shown a benefit in overall survival in GBM ...

Abstract	Glioblastoma (GBM) is the most frequent primary malignant brain tumor and has a dismal prognosis. Unfortunately, despite the recent revolution of immune checkpoint inhibitors in many solid tumors, these have not shown a benefit in overall survival in GBM patients. Therefore, new potential treatment targets as well as diagnostic, prognostic, and/or predictive biomarkers are needed to improve outcomes in this population. The β-galactoside binding protein Galectin-1 (Gal-1) is a protein with a wide range of pro-tumor functions such as proliferation, invasion, angiogenesis, and immune suppression. Here, we evaluated Gal-1 expression by immunohistochemistry in a homogenously treated cohort of GBM (the GLIOCAT project) and correlated its expression with clinical and molecular data. We observed that Gal-1 is a negative prognostic factor in GBM. Interestingly, we observed higher levels of Gal-1 expression in the mesenchymal/classical subtypes compared to the less aggressive proneural subtype. We also observed a Gal-1 expression correlation with immune suppressive signatures of CD4 T-cells and macrophages, as well as with several GBM established biomarkers, including SHC1, PD-L1, PAX2, MEOX2, YKL-40, TCIRG1, YWHAG, OLIG2, SOX2, Ki-67, and SOX11. Moreover, Gal-1 levels were significantly lower in grade 4
MeSH term(s)	Humans ; Galectin 1/genetics ; Galectin 1/metabolism ; Prognosis ; Glioblastoma/diagnosis ; Glioblastoma/genetics ; Glioblastoma/metabolism ; Astrocytoma/metabolism ; Biomarkers ; Vacuolar Proton-Translocating ATPases/metabolism ; 14-3-3 Proteins/metabolism
Chemical Substances	Galectin 1 ; Biomarkers ; TCIRG1 protein, human ; Vacuolar Proton-Translocating ATPases (EC 3.6.1.-) ; YWHAG protein, human ; 14-3-3 Proteins
Language	English
Publishing date	2023-03-08
Publishing country	Switzerland
Document type	Multicenter Study ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2661518-6
ISSN	2073-4409 ; 2073-4409
ISSN (online)	2073-4409
ISSN	2073-4409
DOI	10.3390/cells12060843
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Amyloid Beta-Peptide Increases BACE1 Translation through the Phosphorylation of the Eukaryotic Initiation Factor-2

Picón-Pagès, Pol / Gutiérrez, Daniela A / Barranco-Almohalla, Alejandro / Crepin, Giulia / Tajes, Marta / Ill-Raga, Gerard / Guix, Francesc X / Menéndez, Silvia / Arumí-Uría, Montserrat / Vicente, Rubén / Álvarez, Alejandra R / Muñoz, Francisco J

Oxidative medicine and cellular longevity

2020 Volume 2020, Page(s) 2739459

Abstract: Alzheimer's disease (AD) is tightly linked to oxidative stress since amyloid beta-peptide ( ... ...

Abstract	Alzheimer's disease (AD) is tightly linked to oxidative stress since amyloid beta-peptide (A
MeSH term(s)	5' Untranslated Regions ; Alzheimer Disease/metabolism ; Alzheimer Disease/pathology ; Amyloid Precursor Protein Secretases/genetics ; Amyloid Precursor Protein Secretases/metabolism ; Amyloid beta-Peptides/pharmacology ; Cell Line, Tumor ; Cell Survival/drug effects ; Eukaryotic Initiation Factor-2/metabolism ; Hippocampus/metabolism ; Hippocampus/pathology ; Humans ; Hydrogen Peroxide/pharmacology ; Oxidative Stress ; Phosphorylation ; Up-Regulation/drug effects
Chemical Substances	5' Untranslated Regions ; Amyloid beta-Peptides ; Eukaryotic Initiation Factor-2 ; Hydrogen Peroxide (BBX060AN9V) ; Amyloid Precursor Protein Secretases (EC 3.4.-)
Language	English
Publishing date	2020-09-19
Publishing country	United States
Document type	Journal Article
ZDB-ID	2455981-7
ISSN	1942-0994 ; 1942-0994
ISSN (online)	1942-0994
ISSN	1942-0994
DOI	10.1155/2020/2739459
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Dysplastic nevus: the eye of the hurricane.

Arumi-Uria, Montserrat

Journal of cutaneous pathology

2008 Volume 35 Suppl 2, Page(s) 16–19

Abstract: Dysplastic nevi were generally recognized, thanks to the contributions of Clark et al. in 1978. These lesions were described in a familial context, which was called the 'B-K mole syndrome'. However, it is worth noting that this was not the first time ... ...

Abstract	Dysplastic nevi were generally recognized, thanks to the contributions of Clark et al. in 1978. These lesions were described in a familial context, which was called the 'B-K mole syndrome'. However, it is worth noting that this was not the first time that these nevi had been described in the literature. If we look back in history, we can find that in 1820, Norris had already described some very similarly pigmented lesions, also in a familial context, just as Cawley subsequently did in 1952. Clark coined the term of dysplastic nevi for lesions presenting in patients with personal and family histories of malignant melanoma, having from 10 to 100 nevus lesions of a certain size, irregular shape and variable pigmentation of more than 5 mm. In addition, he pointed out that histologically, such lesions were principally characterized by the presence of atypical melanocytic hyperplasia.
MeSH term(s)	Dysplastic Nevus Syndrome/epidemiology ; Dysplastic Nevus Syndrome/history ; Dysplastic Nevus Syndrome/pathology ; History, 20th Century ; History, 21st Century ; Humans
Language	English
Publishing date	2008-11
Publishing country	United States
Document type	Historical Article ; Journal Article ; Review
ZDB-ID	187078-6
ISSN	1600-0560 ; 0303-6987
ISSN (online)	1600-0560
ISSN	0303-6987
DOI	10.1111/j.1600-0560.2008.01142.x
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1043: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Gal-1 Expression Analysis in the GLIOCAT Multicenter Study

Cells, Vol 12, Iss 843, p

Role as a Prognostic Factor and an Immune-Suppressive Biomarker

2023 Volume 843

Abstract	Glioblastoma (GBM) is the most frequent primary malignant brain tumor and has a dismal prognosis. Unfortunately, despite the recent revolution of immune checkpoint inhibitors in many solid tumors, these have not shown a benefit in overall survival in GBM patients. Therefore, new potential treatment targets as well as diagnostic, prognostic, and/or predictive biomarkers are needed to improve outcomes in this population. The β-galactoside binding protein Galectin-1 (Gal-1) is a protein with a wide range of pro-tumor functions such as proliferation, invasion, angiogenesis, and immune suppression. Here, we evaluated Gal-1 expression by immunohistochemistry in a homogenously treated cohort of GBM (the GLIOCAT project) and correlated its expression with clinical and molecular data. We observed that Gal-1 is a negative prognostic factor in GBM. Interestingly, we observed higher levels of Gal-1 expression in the mesenchymal/classical subtypes compared to the less aggressive proneural subtype. We also observed a Gal-1 expression correlation with immune suppressive signatures of CD4 T-cells and macrophages, as well as with several GBM established biomarkers, including SHC1, PD-L1, PAX2, MEOX2, YKL-40, TCIRG1, YWHAG, OLIG2, SOX2, Ki-67, and SOX11. Moreover, Gal-1 levels were significantly lower in grade 4 IDH-1 mutant astrocytomas, which have a better prognosis. Our results confirm the role of Gal-1 as a prognostic factor and also suggest its value as an immune-suppressive biomarker in GBM.
Keywords	Galectin-1 ; glioblastoma ; prognostic factor ; IDH-1 ; mesenchymal molecular subtype ; immune-suppression ; Biology (General) ; QH301-705.5
Subject code	570 ; 616
Language	English
Publishing date	2023-03-01T00:00:00Z
Publisher	MDPI AG
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report.

Casadevall, David / Vidal, Joana / Gallardo, Fernando / Zuccarino, Flavio / Arumí-Uría, Montserrat / Dalmases, Alba / Bellosillo, Beatriz / Montagut, Clara

Journal of medical case reports

2016 Volume 10, Issue 1, Page(s) 158

Abstract: Background: Approximately 50 % of malignant melanomas harbor activating point mutations in the BRAF gene. Typically, these mutations result in the substitution of the amino acid valine at codon 600 of the gene, and 90-95 % of mutations are either BRAF ( ... ...

Abstract	Background: Approximately 50 % of malignant melanomas harbor activating point mutations in the BRAF gene. Typically, these mutations result in the substitution of the amino acid valine at codon 600 of the gene, and 90-95 % of mutations are either BRAF (V600E) or BRAF (V600K). Specific BRAF inhibitors such as dabrafenib and vemurafenib are the mainstays of treatment in patients with metastatic BRAF-mutant malignant melanomas. The third most common BRAF mutation is V600R, which also leads to increased BRAF signaling. Although evidence exists about the activity of dabrafenib and vemurafenib in patients with the BRAF (V600R) mutation, these patients have been systematically excluded from recent trials with targeted therapies. Case presentation: Here, we report the positive results in terms of survival and quality of life obtained with dabrafenib in an 80-year-old Caucasian male patient with a Charlson Comorbidity Index of 8 diagnosed with metastatic malignant melanoma harboring the BRAF (V600R) mutation. Our patient was treated with dabrafenib for 7 months with minimal toxicity. We also report exploratory analyses of circulating tumor DNA during targeted treatment. Interestingly, the mutation was not detected after starting treatment and became detectable before radiological disease progression. Conclusions: Our report suggests that (1) a relevant benefit can be obtained with a BRAF inhibitor in real-world patients with a malignant melanoma harboring a BRAF (V600R) mutation, and that (2) circulating tumor DNA detection might be of help in assessing tumor burden in everyday clinical practice. The results reported here should encourage the inclusion of patients with BRAF (V600R)-mutated malignant melanomas in future prospective clinical trials with BRAF inhibitors.
MeSH term(s)	Aged, 80 and over ; Antineoplastic Agents/therapeutic use ; Brain Neoplasms/diagnostic imaging ; Brain Neoplasms/secondary ; Ear Neoplasms/drug therapy ; Ear Neoplasms/genetics ; Ear Neoplasms/pathology ; Humans ; Imidazoles/therapeutic use ; Liver Neoplasms/diagnostic imaging ; Liver Neoplasms/drug therapy ; Liver Neoplasms/secondary ; Lung Neoplasms/diagnostic imaging ; Lung Neoplasms/drug therapy ; Lung Neoplasms/secondary ; Magnetic Resonance Imaging ; Male ; Melanoma/diagnostic imaging ; Melanoma/drug therapy ; Melanoma/genetics ; Melanoma/secondary ; Mutation ; Oximes/therapeutic use ; Proto-Oncogene Proteins B-raf/genetics ; Quality of Life ; Skin Neoplasms/drug therapy ; Skin Neoplasms/genetics ; Skin Neoplasms/pathology ; Tomography, X-Ray Computed ; Treatment Outcome
Chemical Substances	Antineoplastic Agents ; Imidazoles ; Oximes ; BRAF protein, human (EC 2.7.11.1) ; Proto-Oncogene Proteins B-raf (EC 2.7.11.1) ; dabrafenib (QGP4HA4G1B)
Language	English
Publishing date	2016-06-02
Publishing country	England
Document type	Case Reports ; Journal Article
ZDB-ID	2269805-X
ISSN	1752-1947 ; 1752-1947
ISSN (online)	1752-1947
ISSN	1752-1947
DOI	10.1186/s13256-016-0953-0
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Full text

Order via subito

Details ▾
- Full text online
- Order with fees

Article: Expression of the proteoglycans versican and mel-CSPG in dysplastic nevi.

Touab, Malika / Arumi-Uría, Montserrat / Barranco, Carlos / Bassols, Anna

American journal of clinical pathology

2003 Volume 119, Issue 4, Page(s) 587–593

Abstract: Nevi with architectural disorder and cytologic atypia of melanocytes (NAD) (also called dysplastic nevi) have been controversial with regard to their relationship with melanoma risk and to their gradation in 3 degrees of atypia. Versican and the melanoma- ...

Abstract	Nevi with architectural disorder and cytologic atypia of melanocytes (NAD) (also called dysplastic nevi) have been controversial with regard to their relationship with melanoma risk and to their gradation in 3 degrees of atypia. Versican and the melanoma-associated proteoglycan (mel-CSPG) are 2 major proteoglycans expressed by malignant melanoma, and they have a role in the regulation of cell adhesion, migration, and differentiation. We evaluated the differences in versican and mel-CSPG expression in nevi, NAD with several degrees of atypia, and primary malignant melanoma. Immunoreactivity for versican was negative in benign melanocytic nevi, positive in NAD (ranging from weakly to intensely positive), and intensely positive in malignant melanoma. Immunostaining for mel-CSPG was negative in benign melanocytic nevi and mild to moderately positive in NAD and melanoma. Our results suggest that versican expression may be of value for distinguishing NAD from benign melanocytic nevi and for distinguishing severe NAD from mild and moderate NAD.
MeSH term(s)	Aggrecans ; Biomarkers, Tumor/metabolism ; Chondroitin Sulfate Proteoglycans/metabolism ; Dysplastic Nevus Syndrome/metabolism ; Dysplastic Nevus Syndrome/pathology ; Extracellular Matrix Proteins ; Glycoproteins/metabolism ; Humans ; Immunoenzyme Techniques ; Lectins, C-Type ; Melanocytes/metabolism ; Melanocytes/pathology ; Melanoma/metabolism ; Melanoma/pathology ; Neoplasm Proteins/metabolism ; Proteoglycans/metabolism ; Skin Neoplasms/metabolism ; Skin Neoplasms/pathology ; Versicans
Chemical Substances	Aggrecans ; Biomarkers, Tumor ; Chondroitin Sulfate Proteoglycans ; Extracellular Matrix Proteins ; Glycoproteins ; Lectins, C-Type ; Neoplasm Proteins ; Proteoglycans ; VCAN protein, human ; Versicans (126968-45-4)
Language	English
Publishing date	2003-04
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2944-0
ISSN	1943-7722 ; 0002-9173
ISSN (online)	1943-7722
ISSN	0002-9173
DOI	10.1309/ME25-J1G5-ENE5-7LM3
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ud II Zs.91: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Cytoplasmic accumulation of NCoR in malignant melanoma: consequences of altered gene repression and prognostic significance.

Gallardo, Fernando / Padrón, Andreina / Garcia-Carbonell, Ricard / Rius, Cristina / González-Perez, Abel / Arumí-Uria, Montserrat / Iglesias, Mar / Nonell, Lara / Bellosillo, Beatriz / Segura, Sonia / Pujol, Ramon Maria / Lopez-Bigas, Nuria / Bertran, Joan / Bigas, Anna / Espinosa, Lluís

Oncotarget

2015 Volume 6, Issue 11, Page(s) 9284–9294

Abstract: Invasive malignant melanoma (MM) is an aggressive tumor with no curative therapy available in advanced stages. Nuclear corepressor (NCoR) is an essential regulator of gene transcription, and its function has been found deregulated in different types of ... ...

Abstract	Invasive malignant melanoma (MM) is an aggressive tumor with no curative therapy available in advanced stages. Nuclear corepressor (NCoR) is an essential regulator of gene transcription, and its function has been found deregulated in different types of cancer. In colorectal cancer cells, loss of nuclear NCoR is induced by Inhibitor of kappa B kinase (IKK) through the phosphorylation of specific serine residues. We here investigate whether NCoR function impacts in MM, which might have important diagnostic and prognostic significance. By IHC, we here determined the subcellular distribution of NCoR in a cohort of 63 primary invasive MM samples, and analyzed its possible correlation with specific clinical parameters. We therefore used a microarray-based strategy to determine global gene expression differences in samples with similar tumor stage, which differ in the presence of cytoplasmic or nuclear NCoR. We found that loss of nuclear NCoR results in upregulation of a specific cancer-related genetic signature, and is significantly associated with MM progression. Inhibition of IKK activity in melanoma cells reverts NCoR nuclear distribution and specific NCoR-regulated gene transcription. Analysis of public database demonstrated that inactivating NCoR mutations are highly prevalent in MM, showing features of driver oncogene.
MeSH term(s)	Adult ; Aged ; Aged, 80 and over ; Carcinogenesis/pathology ; Cell Nucleus/metabolism ; Cytoplasm/metabolism ; Female ; Gene Expression Regulation, Neoplastic/genetics ; Humans ; I-kappa B Kinase/antagonists & inhibitors ; Male ; Melanoma/genetics ; Melanoma/mortality ; Melanoma/pathology ; Middle Aged ; Nuclear Receptor Co-Repressor 1/genetics ; Nuclear Receptor Co-Repressor 1/metabolism ; Phosphorylation ; Signal Transduction/genetics ; Skin Neoplasms ; Transcription Factor RelA/metabolism ; Transcription, Genetic/genetics ; Transcriptional Activation/genetics ; Melanoma, Cutaneous Malignant
Chemical Substances	NCOR1 protein, human ; Nuclear Receptor Co-Repressor 1 ; RELA protein, human ; Transcription Factor RelA ; I-kappa B Kinase (EC 2.7.11.10)
Language	English
Publishing date	2015-03-28
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2560162-3
ISSN	1949-2553 ; 1949-2553
ISSN (online)	1949-2553
ISSN	1949-2553
DOI	10.18632/oncotarget.3252
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer.

Cañadas, Israel / Rojo, Federico / Taus, Álvaro / Arpí, Oriol / Arumí-Uría, Montserrat / Pijuan, Lara / Menéndez, Silvia / Zazo, Sandra / Dómine, Manuel / Salido, Marta / Mojal, Sergi / García de Herreros, Antonio / Rovira, Ana / Albanell, Joan / Arriola, Edurne

Clinical cancer research : an official journal of the American Association for Cancer Research

2014 Volume 20, Issue 4, Page(s) 938–950

Abstract: Purpose: Met receptor phosphorylation is associated with poor prognosis in human small cell lung cancer (SCLC). The aim of our work was to investigate the effects of hepatocyte growth factor (HGF)/Met-mediated epithelial-to-mesenchymal transition (EMT) ... ...

Abstract	Purpose: Met receptor phosphorylation is associated with poor prognosis in human small cell lung cancer (SCLC). The aim of our work was to investigate the effects of hepatocyte growth factor (HGF)/Met-mediated epithelial-to-mesenchymal transition (EMT) in SCLC and to evaluate the role of Met inhibition in mesenchymal/chemorefractory SCLC models. Experimental design: SCLC models of HGF-induced EMT were evaluated in vitro and in vivo (subcutaneous xenografts in BALB/c nude mice) for chemosensitivity and response to Met inhibition with PF-2341066 (crizotinib). Human SCLC samples at diagnosis (N = 87) and relapse (N = 5) were evaluated by immunohistochemistry and immunofluorescence for EMT markers and Met status and these were correlated with patient outcome. Results: We identified that the activation of the Met receptor through HGF induced expression of mesenchymal markers, an aggressive phenotype, and chemoresistance. Blockade of this process with the Met inhibitor resensitized cells to chemotherapy in vitro and in vivo. Moreover, mesenchymal markers in human SCLC specimens were associated with Met activation, predicted worse survival, and were upregulated in chemorefractory disease. Conclusion: These results provide novel evidence on an important role of Met-dependent EMT in the adverse clinical behavior of SCLC and support clinical trials of Met inhibitors and chemotherapy in this fatal disease.
MeSH term(s)	Animals ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Carcinogenesis ; Cell Line, Tumor ; Drug Resistance, Neoplasm ; Drug Synergism ; Epithelial-Mesenchymal Transition/drug effects ; Etoposide/pharmacology ; Etoposide/therapeutic use ; Gene Expression ; Hepatocyte Growth Factor/physiology ; Humans ; Kaplan-Meier Estimate ; Lung Neoplasms/drug therapy ; Lung Neoplasms/enzymology ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology ; Male ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Molecular Targeted Therapy ; Piperidines/pharmacology ; Piperidines/therapeutic use ; Proto-Oncogene Proteins c-met/antagonists & inhibitors ; Proto-Oncogene Proteins c-met/metabolism ; Pyrazoles ; Pyridines/pharmacology ; Pyridines/therapeutic use ; Small Cell Lung Carcinoma/drug therapy ; Small Cell Lung Carcinoma/enzymology ; Small Cell Lung Carcinoma/mortality ; Small Cell Lung Carcinoma/pathology ; Snail Family Transcription Factors ; Transcription Factors/genetics ; Transcription Factors/metabolism ; Xenograft Model Antitumor Assays
Chemical Substances	Antineoplastic Agents ; HGF protein, human ; Piperidines ; Pyrazoles ; Pyridines ; Snail Family Transcription Factors ; Transcription Factors ; crizotinib (53AH36668S) ; Hepatocyte Growth Factor (67256-21-7) ; Etoposide (6PLQ3CP4P3) ; MET protein, human (EC 2.7.10.1) ; Proto-Oncogene Proteins c-met (EC 2.7.10.1)
Language	English
Publishing date	2014-02-15
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1225457-5
ISSN	1557-3265 ; 1078-0432
ISSN (online)	1557-3265
ISSN	1078-0432
DOI	10.1158/1078-0432.CCR-13-1330
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4223: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Versican is differentially expressed in human melanoma and may play a role in tumor development.

Touab, Malika / Villena, Juan / Barranco, Carlos / Arumí-Uría, Montserrat / Bassols, Anna

The American journal of pathology

2002 Volume 160, Issue 2, Page(s) 549–557

Abstract: Undifferentiated human melanoma cell lines produce a large chondroitin sulfate proteoglycan, different from the well-known melanoma-specific proteoglycan mel-PG (Heredia and colleagues, Arch Biochem Biophys, 333: 198-206, 1996). We have identified this ... ...

Abstract	Undifferentiated human melanoma cell lines produce a large chondroitin sulfate proteoglycan, different from the well-known melanoma-specific proteoglycan mel-PG (Heredia and colleagues, Arch Biochem Biophys, 333: 198-206, 1996). We have identified this proteoglycan as versican and analyzed the expression of versican in several human melanoma cell lines. Versican isoforms are expressed in undifferentiated cell lines but not in differentiated cells, and the isoform expression pattern depends on the degree of cell differentiation. The V0 and V1 isoforms are found on cells with an early degree of differentiation, whereas the V1 isoform is present in cells with an intermediate degree of differentiation. We have also characterized some functional properties of versican on human melanoma cells: the purified proteoglycan stimulates cell growth and inhibits cell adhesion when cells are grown on fibronectin or collagen type I as substrates, and thus may facilitate tumor cell detachment and proliferation. Furthermore, we have analyzed the expression of versican in human melanocytic nevi and melanoma: 10 benign melanocytic nevi, 10 dysplastic nevi, 11 primary malignant melanomas, and 8 metastatic melanomas were tested. Immunoreactivity for versican was negative in benign melanocytic nevi, weakly to strongly positive in dysplastic nevi, and intensely positive in primary malignant melanomas and metastatic melanomas. Our results indicate that versican is involved in the progression of melanomas and may be a reliable marker for clinical diagnosis.
MeSH term(s)	Astrocytoma/metabolism ; Cell Adhesion/physiology ; Cell Differentiation/physiology ; Cell Division/physiology ; Chondroitin Sulfate Proteoglycans/chemistry ; Chondroitin Sulfate Proteoglycans/genetics ; Chondroitin Sulfate Proteoglycans/metabolism ; Humans ; Immunohistochemistry ; Lectins, C-Type ; Melanoma/metabolism ; Melanoma/pathology ; Protein Isoforms ; Proteoglycans/chemistry ; Proteoglycans/genetics ; Proteoglycans/metabolism ; Tumor Cells, Cultured ; Versicans
Chemical Substances	Chondroitin Sulfate Proteoglycans ; Lectins, C-Type ; Protein Isoforms ; Proteoglycans ; VCAN protein, human ; Versicans (126968-45-4)
Language	English
Publishing date	2002-02
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2943-9
ISSN	1525-2191 ; 0002-9440
ISSN (online)	1525-2191
ISSN	0002-9440
DOI	10.1016/S0002-9440(10)64874-2
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ud II Zs.76: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Grading of atypia in nevi: correlation with melanoma risk.

Arumi-Uria, Montserrat / McNutt, N Scott / Finnerty, Bridget

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

2003 Volume 16, Issue 8, Page(s) 764–771

Abstract: Nevi with architectural disorder and cytologic atypia of melanocytes (NAD), aka "dysplastic nevi," have varying degrees of histologic abnormalities, which can be considered on a spectrum of grades of atypia. Somewhat controversial and subjective criteria ...

Abstract	Nevi with architectural disorder and cytologic atypia of melanocytes (NAD), aka "dysplastic nevi," have varying degrees of histologic abnormalities, which can be considered on a spectrum of grades of atypia. Somewhat controversial and subjective criteria have been developed for grading of NAD into three categories "mild," "moderate," and "severe." Grading involves architectural and cytological features, which often correlate with each other. Architectural criteria were intraepidermal junctional extension beyond any dermal component, complex distortion of rete ridges, and dermal fibrosis. Cytological criteria were based on nuclear size, dispersion of chromatin, prominence of nucleoli, hyperchromasia and variation in nuclear staining. Few tests have been made of the relationship between specific grades of atypia and patient risk for melanoma. Retrospective review of pathology reports was performed on 20,275 nevi examined between 1989 and 1996. From the total, 6,275 were diagnosed as NAD, which were in 4,481 patients. These patients were divided into those whose worst NAD was mild (2,504), moderate (1,657), or severe (320). Review of accession data revealed that a personal history of melanoma was present in 5.7% of patients with mild, 8.1% with moderate, and 19.7% with severe atypia. The male/female ratios were similar in each group. In the three groups, the mean ages of men were similar and of women were similar, but the mean age of men tended to be 6-11 yrs. older than women in each group. Family histories of melanoma were not considered. The odds ratio as a measure of association between NAD and personal history of melanoma, shows an odds ratio of 4.08 (2.91-5.7) for NAD-severe versus NAD mild, odds ratio 2.81 (2-3.95) for NAD-severe versus NAD-moderate and odds ratio 1.45 (1.13-1.87) for NAD moderate versus NAD-mild. These data show that the probability of having personal history of melanoma, for any given NAD patient, correlates with the NAD grade. Likewise, the risk of melanoma is greater for persons who tend to make nevi with high grade histological atypia.
MeSH term(s)	Adolescent ; Adult ; Age Factors ; Aged ; Aged, 80 and over ; Dysplastic Nevus Syndrome/pathology ; Female ; Humans ; Male ; Melanoma/pathology ; Middle Aged ; Odds Ratio ; Precancerous Conditions/pathology ; Retrospective Studies ; Risk Factors ; Skin Neoplasms/pathology
Language	English
Publishing date	2003-08
Publishing country	United States
Document type	Comparative Study ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	645073-8
ISSN	1530-0285 ; 0893-3952
ISSN (online)	1530-0285
ISSN	0893-3952
DOI	10.1097/01.MP.0000082394.91761.E5
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2450: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito